RNA Contaminates Glycosaminoglycans Extracted from Cells and Tissues.

Glycosaminoglycans (GAGs) are linear negatively charged polysaccharides and important components of extracellular matrices and cell surface glycan layers such as the endothelial glycocalyx. The GAG family includes sulfated heparin, heparan sulfate (HS), dermatan sulfate (DS), chondroitin sulfate (CS), keratan sulfate, and non-sulfated hyaluronan. Because relative expression of GAGs is dependent on cell-type and niche, isolating GAGs from cell cultures and tissues may provide insight into cell- and tissue-specific GAG structure and functions. In our objective to obtain structural information about the GAGs expressed on a specialized mouse glomerular endothelial cell culture (mGEnC-1) we adapted a recently published GAG isolation protocol, based on cell lysis, proteinase K and DNase I digestion. Analysis of the GAGs contributing to the mGEnC-1 glycocalyx indicated a large HS and a minor CS content on barium acetate gel. However, isolated GAGs appeared resistant to enzymatic digestion by heparinases. We found that these GAG extracts were heavily contaminated with RNA, which co-migrated with HS in barium acetate gel electrophoresis and interfered with 1,9-dimethylmethylene blue (DMMB) assays, resulting in an overestimation of GAG yields. We hypothesized that RNA may be contaminating GAG extracts from other cell cultures and possibly tissue, and therefore investigated potential RNA contaminations in GAG extracts from two additional cell lines, human umbilical vein endothelial cells and retinal pigmental epithelial cells, and mouse kidney, liver, spleen and heart tissue. GAG extracts from all examined cell lines and tissues contained varying amounts of contaminating RNA, which interfered with GAG quantification using DMMB assays and characterization of GAGs by barium acetate gel electrophoresis. We therefore recommend routinely evaluating the RNA content of GAG extracts and propose a robust protocol for GAG isolation that includes an RNA digestion step.

Efficacy of intramuscular polysulfated glycosaminoglycan in a controlled study of equine carpitis.

Twelve healthy horses were subject to the monoioidoacetate (MIA) carpitis model, which was allowed to develop for 7 days. The horses were then randomly divided into two groups. Group A (control) received an intramuscular injection of normal saline every 4 days for a total of seven injections while group B received 500 mg of a PSGAG (SYNTEX CSY36) intramuscularly every 4 days for seven treatments. Efficacy of the PSGAG was evaluated by three clinical outcomes: lameness score, carpal circumference and maximum carpal flexion. Clinical outcomes were measured on days -8 (previous to carpitis induction), 0 (previous to drug treatment), 7, 14, 21, 28 and 35. Areas under the curve clinical outcome as function of time were built and used as variables for the statistical analysis. There was less joint circumference enlargement and lameness and greater carpal flexion in PSGAG-treated horses compared with that in controls. The studied compound has demonstrated to be efficacious on the treatment of a chemically induced carpitis in horses.

One-dimensional cellulose acetate plate electrophoresis--a feasible method for analysis of dermatan sulfate and other glycosaminoglycan impurities in pharmaceutical heparin.

A cellulose acetate plate electrophoresis method for analysis of pharmaceutical heparin and its potential glycosaminoglycan impurities, e.g. dermatan sulfate, chondroitin sulfate and oversulfated chondroitin sulfate, is presented. Heparin is chemically degraded by application of nitrous acid and residual glycosaminoglycans are electrophoretically separated thereafter. After staining using Alcian blue 8GS, these glycosaminoglycan impurities can be quantified by means of comparison to a dermatan sulfate standard. Results of a validation study of this analytical method are shown, demonstrating its feasibility for routine use in analytical quality control labs under GMP conditions.

Measurement of glycosaminoglycan release from cartilage explants.

Quantitation of glycosaminoglycans (GAGs) in the form of aggrecan fragments released from cartilage in culture is a simple way to determine the efficacy of different cytokines alone or in combination in simulating cartilage catabolism. Two approaches for GAG assay are described, with special attention being paid to the advantages and limitations of each method.

Isolation of endogenous anticoagulant N-sulfated glycosaminoglycans in human plasma from healthy subjects.

Endogenous N-sulfated glycosaminoglycans (GAGs) comigrating with standard heparin and sensitive to nitrous acid treatment were isolated from plasma of healthy donors. The amount of these compounds was 7-10 microg/ml, and activated partial thromboplastin time, anti-Xa and anti-IIa activities were similar to those of standard heparin of high molecular mass. Analysis with gradient PAGE of the putative endogenous heparin showed a mean molecular mass of 12 kD. These N-sulfated GAGs could be isolated only after removal of binding peptides that impaired purification by ion-exchange chromatography. We used SDS-PAGE as a tool to separate peptides from endogenous GAGs. N-sulfated GAGs exited the gel before peptides when the electrophoresis was overrun. Endogenous GAGs could be recovered by ion-exchange chromatography of the SDS-PAGE buffer, 'free' from associating peptides. These results strongly support the hypothesis that endogenous heparin is associated in vitro with a variety of proteins and that this association could be responsible for modification of both heparin and protein activities.

Treatment of acute superficial digital flexor tendon injury in horses with polysulphated glycosaminoglycan.

Horses with acute injuries of the superficial digital flexor tendon were treated with a course of seven intramuscular injections of 500 mg of polysulphated glycosaminoglycan at four-day intervals. Clinical assessments of the lesions were made by a veterinary surgeon at the time of each injection and 14 and 28 days after the last injection. A total of 150 courses of the drug were administered and adequately completed assessment forms were returned for 80 cases. Long-term follow-up data were obtained for 19 cases. The subjective assessments by the veterinary surgeons showed that in 80 per cent of cases the drug was felt to be of value in the treatment of acute tendon injury.

Diagnostic test for mucopolysaccharidosis. II. Rapid quantification of glycosaminoglycan in urine samples collected on a paper matrix.

The direct 1,9-dimethylmethylene blue (DMB) method for quantifying sulfated glycosaminoglycan (GAG) in urine (Clin Chem 1989; 35:374-9) has been adapted to a convenient means for sample collection and transport as a test to identify individuals with mucopolysaccharidosis (MPS) storage diseases. Results correlated moderately well (r = 0.85) with those of a commonly used, but more laborious, quantitative method. In studying factors to maximize differentiation of pathological from normal values, we found that GAG excretion (expressed as milligrams GAG per gram creatinine) fits a logarithmic function with respect to age and varies markedly below age five years. This must be considered in developing normative values and forming diagnoses. Of 112 separate urine specimens obtained from 41 MPS patients representing the major MPS diseases, glycosaminoglycan excretion by all exceeded that for age-matched normal individuals. The convenience of this method allowed us to establish the first normative values for three-week-old infants (n = 435) found to have a mean glycosaminoglycan excretion of 179 (SD 86.3) mg of GAG per gram of creatinine. This method improves the diagnostic capability for those MPS diseases that have been particularly difficult to identify (Sanfilippo's syndrome and Morquio's syndrome), and may also provide a test for other disorders with previously unrecognized abnormal excretion of glycosaminoglycan (e.g., mucolipidosis and acromesomelic dysplasia). Most importantly, this MPS diagnostic test is unique in its suitability for mass screening of newborn infants.

Estandarización de un método analítico: aplicación a la determinación de glicosaminoaglicanos urinarios / Standardization of a analytical method: aplication to the determination of urinary glycosaminoglycans

Se presenta la estandarización de un método para la determinación cuantitativa de glicosaminoglicanos (GAGs) urinarios, empleando una combinación de los métodos descriptos por Di Ferrante y Bitter y Muir, con algunas modificaciones que debieron ser introducidas para adecuarlo a nuestras condiciones experimentales. La determinación se basa en la precipitación de los GAGs por acción de bromuro de cetiltrimetilamonio, seguida de la hidrólisis del polímero y la posterior reacción colorimétrica con carbazol de los ácidos hexurónicos liberados. Se describen, detalladamente, los estudios de estandarización: determinación de la precisión de las distintas etapas del método, linealidad y carta de control de las pendientes de las curvas de calibración, ensayos de recuperación, investigación de interferencias y variaciones en las condiciones de trabajo. Esta metodología puede servir de base para establecer protocolos de control de cualquier procedimiento analítico

Estandarización de un método analítico: aplicación a la determinación de glicosaminoaglicanos urinarios / Standardization of a analytical method: aplication to the determination of urinary glycosaminoglycans

Se presenta la estandarización de un método para la determinación cuantitativa de glicosaminoglicanos (GAGs) urinarios, empleando una combinación de los métodos descriptos por Di Ferrante y Bitter y Muir, con algunas modificaciones que debieron ser introducidas para adecuarlo a nuestras condiciones experimentales. La determinación se basa en la precipitación de los GAGs por acción de bromuro de cetiltrimetilamonio, seguida de la hidrólisis del polímero y la posterior reacción colorimétrica con carbazol de los ácidos hexurónicos liberados. Se describen, detalladamente, los estudios de estandarización: determinación de la precisión de las distintas etapas del método, linealidad y carta de control de las pendientes de las curvas de calibración, ensayos de recuperación, investigación de interferencias y variaciones en las condiciones de trabajo. Esta metodología puede servir de base para establecer protocolos de control de cualquier procedimiento analítico (AU)